Real-world study finds Mounjaro patients lost 15.2% body weight compared to 7.9% for Ozempic
- Eli Lilly’s Mounjaro is three times more effective than Novo Nordisk’s Ozempic for weight loss
- Patients taking Mounjaro lost an average of 15.2% of their body weight
- Patients taking Ozempic lost an average of 7.9% of their body weight
- Mounjaro and Ozempic are approved for Type 2 diabetes, but Zepbound and Wegovy are approved for weight management
- Mounjaro has generated $2.96 billion in sales for Lilly this year
Eli Lilly’s Mounjaro has been found to be significantly more effective than Novo Nordisk’s Ozempic in producing weight loss, according to a real-world study. The study, which analyzed data from 18,000 patients, found that those taking Mounjaro were three times more likely to achieve a 15% weight loss compared to those taking Ozempic. After one year of treatment, Mounjaro patients lost an average of 15.2% of their body weight, while Ozempic patients lost an average of 7.9%. Both Mounjaro and Ozempic are approved for the treatment of Type 2 diabetes, but their counterparts, Zepbound and Wegovy, are approved for weight management. The study results come as Zepbound is set to hit the market, creating direct competition with Wegovy. The study also found that Mounjaro patients were nearly twice as likely to achieve a 5% weight loss and 2.6 times more likely to achieve a 10% weight loss compared to Ozempic patients. The study showed that weight loss was greater for patients without Type 2 diabetes, and rates of gastrointestinal side effects were similar between the two medications. This real-world study provides valuable data on the effectiveness of Mounjaro and Ozempic, as there has been limited comparative data available. Mounjaro has been a top seller for Lilly, generating $2.96 billion in sales in the first nine months of the year.
Factuality Level: 8
Factuality Justification: The article provides information from a real-world study conducted by Truveta Research, which analyzed de-identified patient data from a collective of health systems. The study found that Eli Lilly’s Mounjaro was more effective than Novo Nordisk’s Ozempic in producing weight loss in patients with overweight or obesity. The article also mentions that both Mounjaro and Ozempic have U.S. regulatory approval for the treatment of Type 2 diabetes, not weight loss, but there are other medications approved for weight management. The article provides data on the percentage of weight loss achieved by patients taking Mounjaro and Ozempic, as well as comparisons of weight loss rates between patients with and without Type 2 diabetes. It also mentions that the study captured data from all patients, not just the insured, allowing for head-to-head comparisons of the drugs’ efficacy. The article includes information on the sales performance of Mounjaro and the stock performance of Eli Lilly and Novo Nordisk.
Noise Level: 7
Noise Justification: The article provides information on a new study comparing the effectiveness of Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic in producing weight loss in patients with overweight or obesity. It includes data from the study and mentions the regulatory approvals of the drugs. However, the article contains some filler content, such as the mention of text-to-speech technology and the request for feedback. It also lacks scientific rigor and intellectual honesty as it does not provide details on the methodology of the study or any potential conflicts of interest. Overall, the article provides some relevant information but is not comprehensive or in-depth.
Financial Relevance: Yes
Financial Markets Impacted: The article provides information about two pharmaceutical companies, Eli Lilly and Novo Nordisk, and their respective drugs Mounjaro and Ozempic. It discusses the effectiveness of Mounjaro in producing weight loss compared to Ozempic, which could have implications for the companies’ market share and sales.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Rating Justification: The article does not mention any extreme events or their impact.
Public Companies: Eli Lilly (LLY), Novo Nordisk (NVO)
Key People:
Reported publicly:
www.marketwatch.com 
